Lilly’s Cialis Sales In China Unimpressive
This article was originally published in PharmAsia News
Executive Summary
A year after Lilly entered China with erectile dysfunction drug Cialis (tadalafil) to compete with Pfizer's Viagra (sildenafil) and Bayer's Levitra (vardenafil), the latest entrant still lags behind the two rivals despite distributing its products to 5,000 drugstores. According to a principal drug chain, Cialis does not present any price advantage to retailers due to Lilly's strictly controlled high retail price. In addition, Viagra's dominant position and Pfizer's strong marketing support for its channels contribute to Cialis' poor take-up rate. Lilly China admits to Viagra having a first-entry advantage; however, the company is confident of Cialis' performance and believes it can compete effectively once the distribution channels are in place. (Click here for more - Chinese Language)
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.